Results 171 to 180 of about 4,580 (188)

The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy

Pediatrics International, 2022
Evrim Hepkaya
exaly  

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study

Neuromuscular Disorders, 2019
Monique Ryan, Wuh-Liang Hwu, Darryl de Vivo   +2 more
exaly  

Plecanatide, Nusinersen, and Obeticholic acid

Journal of the American Pharmacists Association, 2017
Daniel A, Hussar, Deborah K, Douglas
openaire   +2 more sources

Nusinersen/onasemnogene-abeparvovec

Reactions Weekly, 2020
openaire   +2 more sources

Nusinersen/onasemnogene abeparvovec

Reactions Weekly, 2022
openaire   +1 more source

Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: Transforaminal versus conventional approach

Neuromuscular Disorders, 2019
Mauro Bergui, Sara Bortolani, Federica Ricci   +2 more
exaly  

A CSF marker of nusinersen treatment response

Nature Reviews Neurology, 2022
openaire   +2 more sources

Nusinersen: A Treatment for Spinal Muscular Atrophy

Annals of Pharmacotherapy, 2019
Debra Stevens, Cheri Walker
exaly  

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

Lancet, The, 2016
Claudia A Chiriboga, Frank Rigo, Darryl de Vivo   +2 more
exaly  

Ergebnisse zu Nusinersen

NeuroTransmitter, 2018
openaire   +2 more sources